Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Transcenta Holding's EBITDA for the
six
months ended in Dec. 2025 was HK$-99.01 Mil. Transcenta Holding's Revenue for the
six
months ended in Dec. 2025 was HK$5.22 Mil. Therefore, Transcenta Holding's EBITDA margin for the quarter that ended in Dec. 2025 was -1,897.07%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Transcenta Holding EBITDA Margin % Related Terms
Transcenta Holding EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Transcenta Holding's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06628 vs VRTX, REGN, MRNA: EBITDA Margin % Comparison
For the Biotechnology subindustry, Transcenta Holding's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transcenta Holding EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transcenta Holding's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Transcenta Holding's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transcenta Holding (HKSE:06628) has a EBITDA Margin % of -1,897.07% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Transcenta Holding and its competitors. According to the industry distribution chart, Transcenta Holding ranks #819 out of 946 companies in the Biotechnology industry, placing it in the top 86.6%.
Is Transcenta Holding's EBITDA Margin % too high?
Transcenta Holding's current EBITDA Margin % is -1,897.07%. Based on the distribution chart, Transcenta Holding ranks #819 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Transcenta Holding has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Transcenta Holding's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transcenta Holding ranks #819 out of 946 companies for EBITDA Margin %. This places Transcenta Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Transcenta Holding and its competitors. Transcenta Holding's current EBITDA Margin % is -1,897.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transcenta Holding stock overvalued right now?
Based on GuruFocus' analysis, Transcenta Holding (HKSE:06628) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.91 — trading 213.8% above its estimated fair value. The current EBITDA Margin % is -1,897.07%. Transcenta Holding's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Transcenta Holding (HKSE:06628), the current EBITDA Margin % is -1,897.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transcenta Holding (HKSE:06628) Overvalued in 2026?
Based on GuruFocus' analysis, Transcenta Holding stock appears to be overvalued.
The current stock price of HK$0.91 is trading 213.8% above its estimated GF Value™ of HK$0.29.
GuruFocus considers Transcenta Holding to be Significantly Overvalued.
Key valuation signals for HKSE:06628:
EBITDA Margin %: -1,897.07%
GF Value™: HK$0.29 vs. price of HK$0.91 (213.8% above fair value)
No single metric tells the full story. See the HKSE:06628 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capabilities across discovery, research, clinical development, and manufacturing, uniquely positioned to advance high-impact biologic innovations with commercial potential. The company's asset, Osemitamab (TST001), is a anti-Claudin18.2 monoclonal antibody currently advancing toward late-stage development. It is building a differentiated pipeline spanning oncology, osteoporosis, kidney disease, and autoimmune disorders. It operates in a single segment and geographically its operations are spread across Chinese mainland, United States of America, and Others with Chinese Mainland deriving the majority of revenue.
40GF Score
Get the complete analysis for HKSE:06628
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06628 has been successfully added to your 
